Research
EMA Approves New First-line Treatment Option for Metastatic Pancreatic Cancer
Irinotecan hydrochloride trihydrate (Onivyde pegylated liposomal) was approved in March 2024 by the European Medicines Agency (EMA). Indications: N...
Fruquintinib: A New Medicine for mCRC Recommended for Approval in Europe
DiCE supports the recommendation for approval of fruquintinib, a new medicine for metastatic colorectal cancer (mCRC). This medicine offers mCRC pa...
Extending Colonoscopy Screening Intervals: A New Approach to Colorectal Cancer Prevention
Having a colonoscopy is the best way to check and screen for colorectal cancer (CRC). A small camera on a bendy tube is passed through the anus and...
OECD Report Confirms Inequalities in Cancer
Cancer causes almost a quarter of all deaths in the EU27, Norway and Iceland, with five new cancer cases diagnosed every minute in 2022. Assessing ...
Positive Response to New Neoadjuvant Treatment Combination for Gastric and Gastroesophageal Cancer
In a recently published study conducted by the Netherlands Cancer Institute, patients with gastric (stomach) cancer or gastroesophageal junction (G...
Biomarkers and their Role in the Diagnosis and Treatment of Cholangiocarcinoma (CCA)
Researchers in Italy have written a helpful and very detailed review of biomarkers specific to iCCA. Biomarkers are measurable medical signs that c...
Lynch Syndrome, the Most Common of the Rarest
Next month is Lynch Syndrome Day, also known as Hereditary Non-Polyposis Colorectal Cancer, so we will remind people that those who have Lynch synd...
ASCO GI Highlights – Positive Data in Earlier Stage HCC Results
The American Society for Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) was held in San Francisco, USA 18-20 January this year. At ...
Gemcitabine Plus Paclitaxel vs Gemcitabine Alone after FOLFIRINOX in Metastatic Pancreatic Cancer
GEMPAX was an open-label (both researchers and patients know which treatment is being administered), randomised (randomly assigns participants in...
Predictive Values of Blood-based RNA Signature for the FOLFIRINOX/FOLFOX Response in Advanced Pancreatic Cancer
Presently, no widely recognised or established biomarkers are specifically designed to predict the effectiveness of FOLFIRINOX/FOLFOX (chemotherape...
